与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染相关的实质性肺脓肿发展是一种罕见的并发症,文献中只报道了六起主要病例。我们介绍了一例Waldenström巨球蛋白血症患者,该患者在原发性SARS-CoV-2感染后发展为肺脓肿。我们介绍了一名63岁的男性患者,患有SARS-CoV-2感染,并有Waldenström巨球蛋白血症的病史,他在入院两周后出现了空洞性实质内肺脓肿,右下叶有空气-液体水平。患者出现败血症并出现急性呼吸衰竭,需要机械通气和重症监护。他接受了广谱抗生素治疗和吸入性引流,但不幸的是,由于他的严重临床状况,他在初次入院20天后死亡。COVID-19患者肺脓肿的发展,虽然罕见,可能是相当妥协的,甚至是致命的,尤其是免疫功能低下的患者。临床医生应该意识到这种潜在的并发症。
Intraparenchymal lung abscess development associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a rare complication, with only half a dozen primary cases having been reported in the literature. We present the case of a patient with Waldenström\'s macroglobulinemia who developed a lung abscess subsequent to a primary SARS-CoV-2 infection. We present a 63-year-old male patient with SARS-CoV-2 infection and a history of Waldenström\'s macroglobulinemia who developed a cavitating intraparenchymal lung abscess with an air-fluid level in his right lower lobe two weeks following admission to hospital. The patient became septic and developed acute respiratory failure requiring mechanical ventilation and intensive care. He was managed with broad-spectrum antibiotic therapy and aspiration drainage, but unfortunately due to his severe clinical condition died 20 days after his initial admission. The development of a lung abscess in patients with COVID-19, although rare, can be quite compromising and even prove fatal, especially in immunocompromised patients. Clinicians should be aware of this potential complication.